Corporate Webpages Zynex, Inc.
Many in America's aging population suffer from aches and pains
due to arthritis, sciatica, back pains, muscle strain, etc.
Zynex, Inc. (ZYXI) is a maker of medical devices to ease pain,
especially through electronic stimulation, such as one would
find in a transcutaneous electrical nerve stimulation unit (TENS
device). Sales of their medical devices have been growing rapidly.
ZYXI started out as a penny stock in the over-the-counter
bulletin board market, where only a few stocks ever make it from
their to the NASDAQ. As recently as 2016, this stock would have
been in danger of being delisted in on the NASDAQ because of low
share price. But in 2019, the stock began trading on the NASDAQ
with previous history from the OTCBB market. It operates in
three major divisions, devices for pain management, cardiac monitoring,
and devices for neurological diagnosis.
The company is in a very competitive medical device industry
with at least 84 competitors according to one source. The
industry group is recently strong and ZYXI stock is among the
strongest in that group. Analysts are generally favorable, but researchers
entirely divided in their opinions. Institutions are net acquirers.
The company has a very strong Zenith Index indicating good
fundamentals and growth prospects, although the p/e is high due
to a recent extraordinary share price runnup in an upside
breakout pattern still going on. News is generally good maintaining
earnings beating Wall Street expectations for the most part.
The company does considerable business in China although based
in Colorado.
The stock chart recently looks weak and a bit toppy. The
parabolic stop and reverse (SAR) system developed by Welles
Wilder appear to have worked extremely well on this particular
stock with many in-and-out trades recently, with the stock
moving just enough after gaining some momentum to maintain that
momentum long enough to validate signals.
06-24-2020: Zynex, Inc. (ZYXI): Pain Management
(WAIT FOR PAGE TO LOAD COMPLETELY BEFORE LINKS WORK.)
Company Profile
Company History
News
Comparison with Peers
Bond Issue
Zenith Index
Financial Statements
Avg. P/E to Current P/E
Financial Ratios
Intrinsic Value (Disc. CashFlow)
Fair Value Estimator
Projected Earnings
Research Reports
Analysts' Opinions
Insider Activity
Institutional Activity
Sentiment
Short Interest
Standard & Poor's
Management's Discussion
Channel Potential
MACD Histogram
Intraday Chart
Val Idea
Stock Consultant
Point & Figure Chart
Wall Street Analyzer
Marketspace Chart
Time Series Forecast
Neural Network Prediction
Stock Options
Ultimate Trading Systems
Recommendation
Corporate Wepages
Company Profile |
Company History |
News |
Comparison |
Similar Companies Performance:
Bond Issue |
Zenith Index |
Under current market conditions, a Zenith Index Score of 1.20 or above is required for a positive rating on this factor. 1.21 -1.30 is considered acceptable, 1.30-1.40 is considered strong and
> 1.40 is considered exceptionally strong. Accounting statements in this section often contain mistakes, especially in earlier years' totals, but data is deemed sufficient for us to give a rating. More accurate financial statements follow in the next section.
ZYXI Zynex Inc.
Exchange: NASD Group: Medical
Industry: Medical Products
Rank of Industry: 37 Rank within Industry: 93 out of 2
Shares Out: 33.19 (mil.) Market Capitalization:$ 799.00 (mil.)
Sales (12 mo.): $ 45.00 (mil.) Sales Growth: 65.59%
Avg Broker Recommend (1=Strong Buy): 2.00 Consensus Target: 22.41
Dividend:$ 0.00 Yield: 0.00% Payout Ratio: 0.00 Payout Chg: 0.00%
Zynex, Inc. engineers, manufactures, markets, and sells medical devices
for the electrotherapy, and stroke and spinal cord injury rehabilitation
markets primarily in the United States. The company primarily offers
electrotherapy products for pain relief and pain management; and
NeuroMove for stroke and spinal cord injury rehabilitation. The
company's product lines are fully developed, FDA-cleared, commercially
sold, and have been developed to uphold the Company's mission of
improving the quality of life for patients suffering from impaired
mobility due to stroke, spinal cord injury, or debilitating and chronic
pain. Zynex markets its products through commissioned and independent
sales representatives, as well as directly to end users through
advertisements and articles in relevant publications.
Recent Price: 413.00 52-Week High: 27.00 52-Week Low: 7.12
20-Day Avg. Daily Volume = 1,357,625 Beta: 1.12
Earnings per Share (EPS) Estimates:
This Next This Next
Quarter Quarter Year Year
06/2020 09/2020 12/2020 12/2021
Average Estimate 0.00 0.85 0.00 0.00
Number of Estimates 3 3 4 4
Low Estimate 0.06 0.08 0.37 0.55
High Estimate 0.08 0.11 0.47 0.97
Year Ago EPS 0.06 0.06 0.28 0.40
EPS Growth 16.67% 50.00% 42.86% 95.00%
P/E Ratio Related Data: EPS Sales
Current FY Estimate: 80.20 Growth Growth
Trailing 12 Months: 59.78 vs. Previous Quarter: 0.00% 7.53%
P/E Growth Ratio: 0.00 vs. Previous Year: 28.57% 65.59%
Price/Sales Ratio: 15.51 Price/Book Ratio: 34.26 Price/Cash Flow: 76.71
Other Fundamental Data:
03/31/20 12/31/19 09/30/19
Return on Investment 0.00 61.51 71.39
Return on Assets 37.31 40.52 43.31
Current Ratio 4.40 4.34 0.12
Quick Ratio 3.82 3.88 0.65
Operating Margin 19.57 20.87 2.56
Net Margin 19.57 20.87 2.56
Pre-Tax Margin 0.00 0.00 0.00
Book Value 0.60 0.28 0.15
Inventory Turnover 4.51 5.18 0.96
Debt-to-Equity Ratio 0.18 0.17 0.23
Debt-to-Capital Ratio 14.90 14.85 8.87
Reported and Estimated Quarterly Earnings:
Reported 03/2020 12/2019 09/2019 06/2019
0.09 0.09 0.06 0.06
Estimated 06/2020 09/2020 12/2020 12/2021
Consensus 7 Days Ago 0.07 0.09 0.40 0.78
Upward Revisions 0 0 0 0
Downward Revisions 0 0 0 0
Consensus 30 Days Ago 0.07 0.09 0.40 0.74
Upward Revisions 0 0 1 1
Downward Revisions 0 0 0 0
Annual Income Statements ($mil except EPS data):
12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Sales 45.00 32.00 23.00 13.00 12.00
Cost of Goods 9.00 6.00 5.00 4.00 5.00
Gross Profit 37.00 26.00 19.00 10.00 7.00
Selling, Deprec, Amort Expense 26.00 16.00 10.00 9.00 9.00
Income After Deprec + Amortization 11.00 10.00 9.00 1.00 -2.00
Non-Operating Income 1.00 0.00 0.00 0.00 0.00
Interest Expense 0.00 0.00 1.00 0.00 1.00
Pretax Income 12.00 10.00 7.00 0.00 -3.00
Income Taxes 2.00 1.00 0.00 0.00 0.00
Minority Interest 0.00 0.00 0.00 0.00 0.00
Investment Gains/Losses 0.00 0.00 0.00 0.00 0.00
Other Income/Charges 0.00 0.00 0.00 0.00 0.00
Income from Continuing Operations 9.00 10.00 7.00 0.00 -3.00
Extras + Discontined Operations 0.00 0.00 0.00 0.00 0.00
Net Income 0.00 10.00 7.00 0.00 -3.00
Income before Depr. + Amortization 12.00 11.00 10.00 1.00 -2.00
Depreciation + Amort. (Cash Flow) 0.00 0.00 0.00 0.00 0.00
Average Shares 33.96 34.04 33.20 31.27 31.27
Diluted EPS bf Non-Recurring Items 0.28 0.28 0.22 0.00 -0.09
Diluted Net EPS 0.28 0.28 0.22 0.00 -0.09
Balance Sheets ($mil. except per share data):
12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Assets:
Cash + Equivalents 0.00 14.00 10.00 6.00 0.00
Receivables 6.00 3.00 2.00 3.00 2.00
Notes Receivable 0.00 0.00 0.00 0.00 0.00
Inventories 2.00 1.00 0.00 0.00 0.00
Other Current Assets 0.00 1.00 0.00 0.00 0.00
Total Current Assets 23.00 14.00 8.00 3.00 3.00
Property, Plant & Equipment 1.00 1.00 0.00 1.00 1.00
Investments + Advances 0.00 0.00 0.00 0.00 0.00
Other Non-Current Assets 0.00 0.00 0.00 0.00 0.00
Deferred Charges 1.00 1.00 0.00 0.00 0.00
Intangibles 0.00 0.00 0.00 0.00 0.00
Deposits + Other Assets 4.00 0.00 0.00 0.00 0.00
Total Assets 0.00 28.00 16.00 9.00 4.00
12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Liabilities:
Notes Payable 0.00 0.00 0.00 0.00 0.00
Accounts Payable 2.00 2.00 2.00 3.00 2.00
Current Portion Long-Term Debt 1.00 0.00 0.00 3.00 4.00
Current Portion Capital Leases 0.00 0.00 0.00 0.00 0.00
Accrued Expenses 2.00 1.00 1.00 1.00 1.00
Income Taxes Payable 0.00 1.00 0.00 0.00 0.00
Other Current Liabilities 0.00 3.00 1.00 1.00 0.00
Total Current Liabilities 5.00 6.00 4.00 8.00 8.00
Mortgages 0.00 0.00 0.00 0.00 0.00
Deferred Income Taxes 0.00 1.00 0.00 0.00 0.00
Convertible Debt 0.00 0.00 0.00 0.00 0.00
Long-Term Debt 3.00 0.00 0.00 0.00 0.00
Non-Current Capital Leases 0.00 0.00 0.00 0.00 0.00
Other Non-Current Liabilities 0.00 0.00 0.00 0.00 0.00
Minority Interest 0.00 0.00 0.00 0.00 0.00
Total Liabilities 0.00 9.00 7.00 4.00 8.00
12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Shareholder Equity:
Preferred Stock 0.00 0.00 0.00 0.00 0.00
Common Sock 0.00 0.00 0.00 0.00 0.00
Capital Surplus 9.00 8.00 8.00 6.00 6.00
Retained Earnings 14.00 5.00 -2.00 -10.00 -10.00
Other Equity 0.00 0.00 0.00 0.00 0.00
Treasury Stock 4.00 4.00 0.00 0.00 0.00
Total Shareholder Equity 20.00 9.00 5.00 -4.00 -4.00
Total Liabilities+ Owners' Equity 28.00 16.00 9.00 4.00 4.00
Total Common Equity 0.00 0.00 0.00 0.00 0.00
Shares Outstanding 32.70 33.20 32.80 31.20 31.20
Book Value per Share 0.60 0.28 0.15 -0.12 -0.13
Cash Flow Statement:
Operations, Investments, & Financial Activities
12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Net Income 0.00 9.49 9.55 7.37 0.07
Depreciation/Amortization + Deplet 0.78 0.60 0.80 0.44 0.42
Net Change in Assets/Liab. -4.30 -0.39 -1.16 -0.42 1.65
Net Cash f Discontinued Operations 0.00 0.00 0.00 0.00 0.00
Other Operating Activities 0.34 -0.35 1.26 1.69 1.20
Net Cash f Operating Activities 0.00 6.30 9.41 8.26 1.77
Property + Equipment -0.16 -1.08 -0.09 0.00 0.01
Acquisition/Disp. of Subsidiaries 0.00 0.00 0.00 0.00 0.00
Investments 0.00 0.00 0.00 0.00 0.00
Other Investing Activity 0.00 0.00 0.00 -0.23 0.10
Net Cash from Investing -0.16 -1.08 -0.09 -0.23 0.11
Use of Funds
12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Issue (Repurchase) Capital Stock 0.05 -3.26 -0.18 0.00 0.00
Issuance (Repayment) of Debt -0.02 -0.51 0.25 -0.07 -0.06
Increase/Decrease Short-Term Debt 0.00 0.00 -2.77 -1.23 -0.44
Dividends + Distributions 0.00 0.00 0.00 0.00 0.00
Other Financing Acitivies 0.00 0.00 -0.16 0.00 0.00
Net Cash from Financing -2.23 -3.76 -2.86 -1.30 -0.50
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00 0.00
Net Change in Cash + Equivalents 3.91 4.56 5.32 0.24 -0.06
Net Change in Cash & Equivalents
12/31/19 12/31/18 12/31/17 12/31/16 12/31/15
Cash at Beginning of Per. 10.13 5.57 0.25 0.01 0.06
Cash at End of Period 14.04 10.13 5.57 0.25 0.01
Net Change in Cash + Equivalents 3.91 4.56 5.32 0.24 -0.06
Zenith Indices: [Indices near +3.0, or near zero,
or < zero bear special attention.]
P/E Ratio Tests:
Current P/E Ratio < 28? 0.4684 P/E Ratio > 5? 1.0000
P/E Ratio Vs Growth Rate: 0.7170 Forward P/E Ratio < 28? 0.3491
Sales Tests:
Sales < $500 mil.? 3.0000 Sales incr. 25% Yearly? 2.6236
Sales > $340 million? 0.0941 Inventory/Sales < 5%? 1.6000
Balance Sheet Tests:
Debt/Equity Ratio < 0.40? 2.3529 LTD/Net Assets: 3.0000
Debt Reduction: 3.0000 Intangibles/Assets < 10%? 3.0000
Current Ratio > 2? 3.0000 Return on Equity > 9.8%? 3.0000
Earnings Tests:
EPS 5-Yr. Growth > 18%? 3.0000 Operating Margin > 5%? 0.2396
EPS Annual Growth > 0%? 0.0000 Dividend Rate cp 2.7%: 0.0000
Earnings Consistent? 1.6667 Payout Ratio Decreasing? 1.2000
Net Income Increasing 25%? 1.1429 Price<15% below 52-wk Hi? 3.0000
Positive Cash Flow? 1.8187 Price/Book X PE < 22? 0.0107
Profit Margin > 7.5%? 2.7827 Price/Book < 1.6? 0.0467
Profit Margin Increasing? 3.0000 Stock Compared to S+P 500: 3.0000
Price & Float Tests:
Return on Investment>12%? 3.0000 Shares Out > 50 mil.? 0.6638
Return on Assets > 10%? 3.0000 Beta > 1.25?: 1.1200
Price/Sales Ratio < 2.3? 3.0000 Liquidity > 2%? 3.0000
Ownership Tests:
Analyst Following > 2.0? 1.5000 Market Capital'n > 300M? 2.6633
Owner's Equity Increasing?-2.2500 Shares Out Decreasing? 0.9398
ZYXI Overall Zenith Index: 1.9873
Financial Statements |
ZYNEX INC (ZYXI) INCOME STATEMENT Fiscal year ends in December. USD in thousand 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Revenue 11,641 13,313 23,432 31,917 45,472 51,504 Cost of revenue 4,937 3,517 4,819 6,038 8,814 10,431 Gross profit 6,704 9,796 18,613 25,879 36,658 41,073 Operating expenses Sales, General and administrative 9,185 9,156 9,669 15,509 25,592 29,805 Total operating expenses 9,185 9,156 9,669 15,509 25,592 29,805 Operating income -2,481 640 8,944 10,370 11,066 11,268 Interest Expense 503 352 1,450 154 5 0 Other income (expense) -7 -204 0 0 880 -9 Income before taxes -2,991 84 7,494 10,216 11,941 11,259 Provision for income taxes -57 15 129 664 2,449 1,180 Net income from continuing operations -2,934 69 7,365 9,552 9,492 10,079 Other 23 0 0 0 0 0 Net income -2,911 69 7,365 9,552 9,492 10,079 Net income available to common shareholders -2,911 69 7,365 9,552 9,492 10,079 Earnings per share Basic -0.09 0.00 0.23 0.29 0.29 0.31 Diluted -0.09 0.00 0.22 0.28 0.28 0.30 Weighted average shares outstanding Basic 31,271 31,271 32,156 32,503 32,439 32,609 Diluted 31,271 31,271 33,196 34,043 33,963 34,084 ____________________________________________________________________________________________________________________________________________ ZYNEX INC (ZYXI) BALANCE SHEET Fiscal year ends in December. USD in thousand 2015-12 2016-12 2017-12 2018-12 2019-12 Assets Current assets Cash Total cash 8 247 5,565 10,128 14,040 Receivables 2,426 3,028 2,185 2,791 5,833 Inventories 305 107 423 837 2,378 Prepaid expenses 27 40 198 570 315 Total current assets 2,766 3,422 8,371 14,326 22,566 Non-current assets Property, plant and equipment Gross property, plant and equipment 2,432 2,523 1,202 2,281 6,932 Accumulated Depreciation -1,631 -1,943 -1,014 -1,462 -2,063 Net property, plant and equipment 801 580 188 819 4,869 Intangible assets 74 34 0 0 0 Deferred income taxes 0 0 0 725 513 Other long-term assets 55 55 370 314 329 Total non-current assets 930 669 558 1,858 5,711 Total assets 3,696 4,091 8,929 16,184 28,277 Liabilities and stockholders' equity Liabilities Current liabilities Short-term debt 4,002 2,771 231 0 0 Capital leases 109 118 123 0 1,256 Accounts payable 2,477 2,879 2,243 1,552 2,133 Taxes payable 79 94 0 688 52 Accrued liabilities 783 949 538 908 1,748 Deferred revenues 89 54 0 0 0 Other current liabilities 0 880 880 3,207 8 Total current liabilities 7,539 7,745 4,015 6,355 5,197 Non-current liabilities Capital leases 216 136 0 0 3,427 Minority interest -89 -89 -89 -89 -89 Other long-term liabilities 12 12 12 531 0 Total non-current liabilities 139 59 -77 442 3,338 Total liabilities 7,678 7,804 3,938 6,797 8,535 Stockholders' equity Common stock 31 31 33 34 34 Additional paid-in capital 5,832 6,032 7,612 8,157 9,198 Retained earnings -9,845 -9,776 -2,411 4,871 14,356 Treasury stock 0 0 -243 -3,675 -3,846 Total stockholders' equity -3,982 -3,713 4,991 9,387 19,742 Total liabilities and stockholders' equity 3,696 4,091 8,929 16,184 28,277 ____________________________________________________________________________________________________________________________________________ ZYNEX INC (ZYXI) Statement of CASH FLOW Fiscal year ends in December. USD in thousand 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Cash Flows From Operating Activities Net income -2,934 69 7,365 9,552 9,492 10,079 Depreciation & amortization 424 435 286 448 778 870 Investment/asset impairment charges 0 30 0 0 0 0 Deferred income taxes 0 0 0 -725 212 -1,047 Stock based compensation 130 200 66 370 820 1,177 Change in working capital 1,653 -420 -1,162 -607 -4,304 -5,149 Accounts receivable -277 -2,018 843 -606 -3,042 -3,403 Inventory 1,602 198 -316 -414 -2,360 -3,495 Prepaid expenses 223 -14 -473 -372 255 -394 Accounts payable -67 402 0 -515 0 0 Accrued liabilities -20 167 0 370 0 0 Income taxes payable 0 0 0 554 0 0 Other working capital 192 845 -1,216 376 843 2,143 Other non-cash items 1,068 1,455 1,705 370 -695 -759 Net cash provided by operating activities 341 1,769 8,260 9,408 6,303 5,171 Cash Flows From Investing Activities Investments in property, plant, and equipmen 0 0 -87 -1,082 -160 -411 Property, plant, and equipment reductions 9 0 0 0 0 0 Other investing activities 99 -226 0 0 0 0 Net cash used for investing activities 108 -226 -87 -1,082 -160 -411 Cash Flows From Financing Activities Debt issued 0 0 1,035 0 0 0 Debt repayment -64 -72 -781 -507 -19 -26 Common stock issued 0 0 39 176 221 435 Common stock repurchased 0 0 -377 -3,432 -171 0 Dividend paid 0 0 0 0 -2,262 -3 Other financing activities -440 -1,232 -2,771 0 0 0 Net cash provided by (used for) financing -504 -1,304 -2,855 -3,763 -2,231 406 Net change in cash -55 239 5,318 4,563 3,912 5,166 Cash at beginning of period 63 8 247 5,565 10,128 9,419 Cash at end of period 8 247 5,565 10,128 14,040 14,585 Free Cash Flow Operating cash flow 341 1,769 8,260 9,408 6,303 5,171 Capital expenditure 0 0 -87 -1,082 -160 -411 Free cash flow 341 1,769 8,173 8,326 6,143 4,760 ____________________________________________________________________________________________________________________________________________
Average to Current P/E Ratios |
(ZYXI) Zynex Inc.
2015 2016 2017 2018 2019
Annual Earnings: -0.09 0.00 0.22 0.28 0.28
Average Price During Year: 0.21 0.30 2.56 3.41 8.42
P/E Ratio: 2.29 3.02 11.64 12.18 30.08
Average 5-Year P/E Ratio = 11.84
Current Price = 24.34
Previous 5 Quarter Earnings: 0.07 0.06 0.06 0.09 0.09
Current Annualized (Last Four Quarters) Earnings = 0.24
________
Average PE / Current PE = 0.12
--------
...a number above 1.00 is good
1.00 or below is bad
Financial Ratios |
. . . . . . . . . . . . Lowest to Highest, Compared to Industry
Intrinsic Value (DCF) |
Intrinsic Value by Discounted Cash Flow Method:
Fair Value Estimator |
Fair Value Estimate:
Projected Earnings |
Research Reports |
Analysts' Opinions |
Insider Activity |
Institutional Activity |
Institutional Ownership:
Sentiment |
Zenith uses the "sentiment" score above or below 50 to award a positive or negative point in the Decision Matrix.
Short Interest Ratio |
As the short interest rises as a percentage of average daily share volume (Days to Cover), this is considered a measure of negative sentiment. Similarly, a decrease in that percentage is considered positive sentiment.
Standard & Poor's |
Management's Discussion of Results of Operations Excerpts |
Channeling Potential |
The summary below includes a value for `Degree,' which refers on a
scale of 1 to 10 the range of a channel in the period under consi-
deration compared to the total range of price movement. It also looks
for the last closing price to be within the channel, otherwise zeroed.
The `Index' is the `Degree' weighted for volatility. Generally, the
the higher the index, the more suitable is the stock for trading as
a `rolling stock' between channel high and low points.
Results for ZYNEX INC.:
Symbol? ZYXI
Total Months Available: 103
Months in Cycle? 4
Months Covered by Periods: 12
Period 1 Period 2 Period 3
H1 L1 H2 L2 H3 L3
13.10 7.12 11.40 7.51 27.00 7.93
RANGE = 27.00 TO 7.12 Close = 24.00
CHANNEL = 11.40 TO 7.93 Degree = 2
Volatility = 14.46% Index = 2
MACD Histogram Divergence |
The theory is that connecting the two most recent peaks or valleys of the MACD histogram will signal the direction of the next major move.
Intraday Chart |
2 Days:
Val Idea |
3 out of 8 favorable, (negative opinion.)
Stock Consultant |
Point & Figure Chart |
Wall Street Analyzer |
Marketspace Chart |
Time Series Forecast |
Neural Network Prediction |
"Neurostock" can only track long trades. Therefore its performance, as tracked by itself on stocks which are consistently falling, may not appear as good as it could if each "sell" signal were a "short sale."
Ultimate Trading Systems |
2 out of 3 of the ultimate systems favor an upmove.
System Below:
Short term outlook: Positive: Bright Green, Negative: Bright Red
Long term outlook: Postive: Dark Green, Negative: Dark Red.
Recommendation |
| Factors | Weighted Points |
|---|---|
| News | + 1 |
| Comparison | - 1 |
| Industry | + 1 |
| Bond Issue | 0 |
| Zenith Index | + 1 |
| Non-GAAP vs. GAAP Earnings | - 1 |
| Cash Flow | + 1 |
| Average to Current P/E | - 1 |
| Ratios | + 1 |
| Intrinsic Value DCF | - 1 |
| Fair Value Estimator | - 1 |
| Projected Earnings | + 1 |
| Research Reports | + 1 |
| Analysts | + 1 |
| Executive Perquisites | + 1 |
| Insider Activity | - 1 |
| Institutional Activity | + 1 |
| Management Reporting | + 1 |
| Short Interest | + 1 |
| Sentiment | + 1 |
| Standard & Poor's | + 1 |
| MACD Histogram Divergence | - 1 |
| Val Idea | - 1 |
| Stock Consultant | - 1 |
| Point & Figure | + 1 |
| Wall Street Analyzer | - 1 |
| Marketspace Chart | - 1 |
| Time Series Chart | - 1 |
| Neural Network | + 1 |
| Stock Options | + 1 |
| Ultimate Trading Systems | + 1 |
| Total | + 6 |
Place 1,230 shares of Zynex, Inc. (ZYXI) on the Active List.
